Flu Crazy 200 - The Largest Pharmaceutical Companies in the world, by size
Johnson & Johnson
Pfizer Inc
Roche Holding Ltd.
Novartis AG
Merck & Co.,
GlaxoSmithKline plc
Sanofi SA
Abbott Laboratories
Novo-Nordisk A/S
Bayer AG
AstraZeneca plc
Bristol-Myers Squibb Company
Amgen,Inc.
Eli Lilly
Teva Pharmaceutical Industries
Gilead Sciences,Inc.
Takeda Pharmaceutical Company
Celgene Corporation
Allergan,Inc
McKesson Corporation
Astellas Pharma Inc.
Shire PLC
CSL Ltd.
Fresenius SE
Alexion Pharmaceuticals, Inc.
Valeant Pharmaceuticals International,
Cardinal Health, Inc.
Daiichi Sankyo Company
Eisai Co.,Ltd.
Sun Pharmaceutical Industries
Regeneron Pharmaceuticals, Inc.
AmerisourceBergen Corporation
Mylan Inc
Chugai Pharmaceutical Co
Perrigo Company
Vertex Pharmaceuticals Inc
Forest Laboratories,Inc
Elan Corporation plc
Life Technologies Corporation
Herbalife Ltd.
Mitsubishi Tanabe Pharma
UCB S.A.
Watson Pharmaceuticals, Inc.
Taisho Pharmaceutical Holdings
Merck KGaA
Ono Pharmaceutical Co
Aspen Pharmacare Holdings
Kyowa Hakko Kirin
Grifols S.A.
Hospira,Inc
Yunnan Baiyao Group
Dr. Reddy's Laboratories
Shanghai Pharmaceuticals Holding
Actelion Ltd.
Jiangsu Hengrui Medicine
Shionogi & Co
Cipla Ltd
Kangmei Pharmaceutical Co.,
IDEXX Laboratories, Inc.
Shandong Weigao Group
Lupin Limited
Hisamitsu Pharmaceutical Co.,
Dainippon Sumitomo Pharma
Endo Pharmaceuticals Holdings
Warner Chilcott PLC
Galenica AG
H. Lundbeck A/S
BioMarin Pharmaceutical Inc.
PT Kalbe Farma
GlaxoSmithKline Pharmaceuticals Ltd
Dabur India Ltd
Santen Pharmaceutical Co.,
Sichuan Kelun Pharmaceutical
Ranbaxy Laboratories Ltd.
Tianjin Tasly Pharmaceutical
Chr. Hansen Holding
Celesio AG
Shenzhen Hepalink Pharmaceutical
Richter Gedeon Nyrt.
Beijing Tongrentang Co.,
Orion Oyj
Salix Pharmaceuticals Ltd
Medipal Holdings Corp
Shanghai Fosun Pharmaceutical
Suzuken Co., Ltd.
Cadila Healthcare
Jilin Aodong Medicine
China Resources Sanjiu
A Meda AB
Jazz Pharmaceuticals PLC.
Techne Corporation
United Therapeutics Corporation
Amylin Pharmaceuticals, Inc.
Hualan Biological Engineering
ARIAD Pharmaceuticals, Inc.
ONYX Pharmaceuticals, Inc.
Krka, tovarna zdravil,
Harbin Pharmaceutical Group
Zhejiang Hisun Pharmaceutical
Questcor Pharmaceuticals, Inc.
Shijiazhuang Yiling Pharmaceutical
Seattle Genetics, Inc.
Qualicorp SA
Ipsen SA
Hikma Pharmaceuticals plc
Miraca Holdings Inc.
Fleury S.A.
Alkermes Public Limited
GlaxoSmithKline Consumer Healthcare
Kobayashi Pharmaceutical Co.,
Denki Kagaku Kogyo
Medicis Pharmaceutical Corporation
ViroPharma, Inc.
Genomma Lab Internacional
Tsumura & Co.
Vivus, Inc. United
Divi's Laboratories Ltd.
Nippon Kayaku Company
Huadong Medicine Co.,
Beijing SL Pharmaceutical
Gansu Yasheng Industrial
BTG plc United
Guilin Jiqi Pharmaceutical
Zhejiang Medicine Co.,
STADA Arzneimittel AG
Pharmacyclics, Inc.
Sawai Pharmaceutical Co.,
Shenzhen Salubris Pharmaceuticals
S&P Pharmaceutical Co
Piramal Healthcare Limited
Glenmark Pharmaceuticals Ltd
Theravance, Inc.
Tieling Newcity Investment
Zhangzhou Pientzehuang Pharmaceutical
Taro Pharmaceutical Industries
Human Genome Sciences,
Recordati S.p.A.
Impax Laboratories Inc.
Wuhan Humanwell Healthcare
Financiere de Tubize
Chongqing Zhifei Biological
DiaSorin S.p.A.
Beijing Double-Crane Pharmaceutical
Opko Health Inc.
Inner Mongolia Yili
Kyorin Holdings Inc
Ironwood Pharmaceuticals Inc.
China Shineway Pharmaceutical
Almirall S.A.
Amarin Corporation plc
Adcock Ingram Holdings
Corporativo Fragua, S.A.
Rohto Pharmaceutical Co.,
Guangzhou Pharmaceutical Co
Mochida Pharmaceutical Co.,
Toho Holdings Co.,
Par Pharmaceutical Companies,
Halozyme Therapeutics, Inc.
Kaken Pharmaceutical Co.,
Tibet Urban Development
Virbac SA
Jiangxi Jiangzhong Pharmaceutical
Tempo Scan Pacific,
Wockhardt Ltd.
China Medical System
Guilin Sanjin Pharmaceutical
Scinopharm Taiwan, Ltd.
Shanghai RAAS Blood Products Co
BB Biotech AG
Sartorius Stedim Biotech
Akorn, Inc. United
Xizang Haisco Pharmaceutical
Guizhou Bailing Group
Kissei Pharmaceutical Co.,
Tibet Cheezheng Tibet Medicine Co, Inc.
The Medicines Company
AstraZeneca Pharma
Zhejiang Huahai Pharmaceutical
Green Cross Corp
Jiangsu Wuzhong Industrial
Showing posts with label Pfizer. Show all posts
Showing posts with label Pfizer. Show all posts
Tuesday, March 20, 2012
Monday, March 7, 2011
Japan suspends use of pediatric vaccines from Pfizer & Sanofi
Bloomberg is reporting that the Japanese ministry of health has suspended the use of pediatric vaccines from Sanofi Aventis (SAN.PA) and Pfizer (NYSE: PFE), following the deaths of four children, between March 2 and March 4.
Pfizer's Prevenar and Sanofi's ActHIB have been suspended in Japan at least until tomorrow, until a panel can meet to discuss the deaths.
Prevnar is used to protect children from meningitis and pneumonia. While ActHIB is used to prevent Haemophilus influenzae type b.
The Bloomberg article can be found here:
http://www.bloomberg.com/news/2011-03-07/japan-stops-use-of-pfizer-sanofi-vaccines-on-four-deaths-1-.html
Pfizer's Prevenar and Sanofi's ActHIB have been suspended in Japan at least until tomorrow, until a panel can meet to discuss the deaths.
Prevnar is used to protect children from meningitis and pneumonia. While ActHIB is used to prevent Haemophilus influenzae type b.
The Bloomberg article can be found here:
http://www.bloomberg.com/news/2011-03-07/japan-stops-use-of-pfizer-sanofi-vaccines-on-four-deaths-1-.html
Tuesday, February 22, 2011
Vaccine makers shielded from suits says Supreme Court
In a 6-2 vote, the Supreme Court today ruled that vaccine makers cannot be sued outside of a specially designated "vaccine court," created by National Childhood Vaccine Injury Act of 1986.
The justices apparently struggled with some ambiguities in the law, with Justice Scalia writing that the "lack of guidance for design defects [in the drugs] combined with the extensive guidance for the grounds of liability specifically mentioned in the act strongly suggests that design defects were not mentioned because they are not a basis for liability."
However, Justice Sotomayer (with Justice Ginsburg) dissented, saying that
to "pre-empt all design defect claims against vaccine manufacturers for covered vaccines, the majority’s decision leaves a regulatory vacuum in which no one—neither the FDA nor any other federal agency, nor state and federal juries—ensures that vaccine manufacturers adequately take account of scientific and technological advancements.
This concern is especially acute with respect to vaccines that have already been released and marketed to the public. Manufacturers, given the lack of robust competition in the vaccine market, will often have little or no incentive to improve the designs of vaccines that are already generating significant profit margins. Nothing in the text, structure, or legislative history remotely suggests that Congress intended that result."
Links to the Supreme Court decision can be found: here.
The ruling was in response to a case brought by the Bruesewitz family, against Wyeth (now owned by Pfizer, Inc), in which the Breusewitz's claimed that their infant daughter was harmed by toxins in a booster shot.
The justices apparently struggled with some ambiguities in the law, with Justice Scalia writing that the "lack of guidance for design defects [in the drugs] combined with the extensive guidance for the grounds of liability specifically mentioned in the act strongly suggests that design defects were not mentioned because they are not a basis for liability."
However, Justice Sotomayer (with Justice Ginsburg) dissented, saying that
to "pre-empt all design defect claims against vaccine manufacturers for covered vaccines, the majority’s decision leaves a regulatory vacuum in which no one—neither the FDA nor any other federal agency, nor state and federal juries—ensures that vaccine manufacturers adequately take account of scientific and technological advancements.
This concern is especially acute with respect to vaccines that have already been released and marketed to the public. Manufacturers, given the lack of robust competition in the vaccine market, will often have little or no incentive to improve the designs of vaccines that are already generating significant profit margins. Nothing in the text, structure, or legislative history remotely suggests that Congress intended that result."
Links to the Supreme Court decision can be found: here.
The ruling was in response to a case brought by the Bruesewitz family, against Wyeth (now owned by Pfizer, Inc), in which the Breusewitz's claimed that their infant daughter was harmed by toxins in a booster shot.
Pfizer Inc (NYSE: PFE) and plaintiffs settle lawsuits related to clinical trial of antibiotic Trovan
Pfizer Inc (NYSE: PFE) and plaintiffs in the cases related to the clinical trial of antibiotic Trovan, have settled the lawsuits.
Although the suits have been resolved, the tragedy continues for children affected by the trial. The suits alleged that Pfizer conducted clinical trials of the controversial antibiotic "Trovan" on some 200 children without the parents consent. Pfizer says that the 11 children who died during the trial were suffering from meningitis, but the parents disputed this.
Trovan has since been barred from pediatric use and is only available in the US for adult populations, due to side affects.
It looked like the plaintiffs in the case were destined to lose in their next court challenge (at the US Supreme Court), and decided to settle the case.
According to a report by Dow Jones Newswires, "Pfizer Inc. (PFE) said Tuesday it has settled lawsuits stemming from a 1996 clinical trial of the antibiotic Trovan in which 11 Nigerian children died and others suffered health problems.
The New York-based drug maker said the terms of the settlement were confidential. A plaintiffs' attorney in the settlement couldn't be reached.
Pfizer conducted the Trovan trial during in outbreak of cerebral spinal meningitis in Nigeria, with the goal of providing a medicine to treat the disease. Families of the children and the Nigerian government accused the company of experimenting on children without proper consent. Pfizer has maintained it conducted the trial in consultation with Nigerian authorities, and that the deaths were caused by meningitis.
Pfizer previously reached settlements with government bodies in Nigeria."
http://english.capital.gr/News.asp?id=1139967
There is more information about these cases via Law.com (ALM):
"According to Nigerian press reports, the trust fund can pay a maximum of $35,000 per family to those able to prove death or permanent disability due to the 1996 trial of Trovan, an antibiotic that has since been restricted to adult emergency care in America because of its damaging side effects.
Pfizer spokesman Christopher Loder said the settlement is confidential and he could not discuss if there were any other terms. Plaintiffs' lawyer Peter Safirstein of Milberg also declined comment beyond the statement.
The suit accused Pfizer of using the experimental drug without the consent of the parents, and of not telling the families that another acceptable drug was available and was being used by Doctors Without Borders in Nigeria to treat the epidemic. Pfizer denied their allegations.
The families battled Pfizer all the way to the U.S. Supreme Court and back after U.S. District Judge William H. Pauley, III, had dismissed the suit in 2005. As of a hearing on Friday, the case was still in the pre-trial motion stage.
But earlier this month the plaintiffs' cause took a bleak turn when the 2nd Circuit Court of Appeals ruled en banc in a different case that claims against a corporation cannot be brought under the Alien Tort Statute. Rather than risk another dismissal and another appeal that was destined to lose at the next level, the plaintiffs agreed on Friday to settle all claims both in the U.S. and Nigeria.
Pfizer established the $35 million Healthcare/Meningitis Trust Fund as part of settling a suit in 2007 brought by the Kano state government, where the drug trial took place. That settlement also is confidential."
http://www.law.com/jsp/cc/PubArticleCC.jsp?id=1202482854504&Pfizer_Settles_Lawsuits_Over_Drugs_Trials_on_Children_in_Nigeria_
200 Largest Pharmaceutical Companies in the World
http://flucrazy.blogspot.com/2011/02/flucrazy-200-200-largest-pharmaceutical.html
Although the suits have been resolved, the tragedy continues for children affected by the trial. The suits alleged that Pfizer conducted clinical trials of the controversial antibiotic "Trovan" on some 200 children without the parents consent. Pfizer says that the 11 children who died during the trial were suffering from meningitis, but the parents disputed this.
Trovan has since been barred from pediatric use and is only available in the US for adult populations, due to side affects.
It looked like the plaintiffs in the case were destined to lose in their next court challenge (at the US Supreme Court), and decided to settle the case.
According to a report by Dow Jones Newswires, "Pfizer Inc. (PFE) said Tuesday it has settled lawsuits stemming from a 1996 clinical trial of the antibiotic Trovan in which 11 Nigerian children died and others suffered health problems.
The New York-based drug maker said the terms of the settlement were confidential. A plaintiffs' attorney in the settlement couldn't be reached.
Pfizer conducted the Trovan trial during in outbreak of cerebral spinal meningitis in Nigeria, with the goal of providing a medicine to treat the disease. Families of the children and the Nigerian government accused the company of experimenting on children without proper consent. Pfizer has maintained it conducted the trial in consultation with Nigerian authorities, and that the deaths were caused by meningitis.
Pfizer previously reached settlements with government bodies in Nigeria."
http://english.capital.gr/News.asp?id=1139967
There is more information about these cases via Law.com (ALM):
"According to Nigerian press reports, the trust fund can pay a maximum of $35,000 per family to those able to prove death or permanent disability due to the 1996 trial of Trovan, an antibiotic that has since been restricted to adult emergency care in America because of its damaging side effects.
Pfizer spokesman Christopher Loder said the settlement is confidential and he could not discuss if there were any other terms. Plaintiffs' lawyer Peter Safirstein of Milberg also declined comment beyond the statement.
The suit accused Pfizer of using the experimental drug without the consent of the parents, and of not telling the families that another acceptable drug was available and was being used by Doctors Without Borders in Nigeria to treat the epidemic. Pfizer denied their allegations.
The families battled Pfizer all the way to the U.S. Supreme Court and back after U.S. District Judge William H. Pauley, III, had dismissed the suit in 2005. As of a hearing on Friday, the case was still in the pre-trial motion stage.
But earlier this month the plaintiffs' cause took a bleak turn when the 2nd Circuit Court of Appeals ruled en banc in a different case that claims against a corporation cannot be brought under the Alien Tort Statute. Rather than risk another dismissal and another appeal that was destined to lose at the next level, the plaintiffs agreed on Friday to settle all claims both in the U.S. and Nigeria.
Pfizer established the $35 million Healthcare/Meningitis Trust Fund as part of settling a suit in 2007 brought by the Kano state government, where the drug trial took place. That settlement also is confidential."
http://www.law.com/jsp/cc/PubArticleCC.jsp?id=1202482854504&Pfizer_Settles_Lawsuits_Over_Drugs_Trials_on_Children_in_Nigeria_
200 Largest Pharmaceutical Companies in the World
http://flucrazy.blogspot.com/2011/02/flucrazy-200-200-largest-pharmaceutical.html
Friday, February 18, 2011
About Pfizer Inc (NYSE: PFE)
Pfizer, Inc (NYSE: PFE)
About Pfizer, Inc*
235 East 42nd Street, New York, New York 10017
(212) 733-2323
Reveune: $67.8 billion (2010)
I.R.S. Employer Identification Number:
13-5315170
Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer health care products. Every day, we work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with other biopharmaceutical companies, health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
The Company was incorporated under the laws of the State of Delaware on June 2, 1942.
On October 15, 2009, we completed our acquisition of Wyeth. The acquisition was a cash-and-stock transaction valued, based on the closing market price of Pfizer’s common stock on the acquisition date, at $50.40 per share of Wyeth common stock, or a total of approximately $68 billion.
In response to the challenging operating environment, we have taken many steps to strengthen our Company and better position ourselves for the future. The most important of these steps was the acquisition of Wyeth, which has transformed us into a more diversified health care company, with product offerings in human and animal health, including vaccines, biologics, small molecules and nutrition across developed and emerging markets. We believe that our acquisition of Wyeth meaningfully advances, in a single transaction, each of the strategic priorities that we have identified and pursued over the last two years, including:
• Enhancing the in-line and patent-protected pipeline portfolio in key “invest to win” areas of
research where there exist significant unmet medical needs and significant opportunities for innovation and market leadership, such as oncology, pain, inflammation, Alzheimer’s disease, psychoses and diabetes as well as the critical technologies of vaccines and biologics;
• Becoming a top-tier player in biotherapeutics by 2015;
• Accelerating growth in emerging markets;
• Creating new opportunities for established products;
• Investing in complementary businesses; and
• Creating a lower, more flexible cost base for the combined company.
*Source: Form 10-K
. . . . .
Pfizer and plaintiffs settle lawsuits
http://flucrazy.blogspot.com/2011/02/pfizer-inc-nyse-pfe-and-plaintiffs.html
200 Largest Pharmaceutical Companies in the World
http://flucrazy.blogspot.com/2011/02/flucrazy-200-200-largest-pharmaceutical.html
About Pfizer, Inc*
235 East 42nd Street, New York, New York 10017
(212) 733-2323
Reveune: $67.8 billion (2010)
I.R.S. Employer Identification Number:
13-5315170
Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer health care products. Every day, we work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with other biopharmaceutical companies, health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
The Company was incorporated under the laws of the State of Delaware on June 2, 1942.
On October 15, 2009, we completed our acquisition of Wyeth. The acquisition was a cash-and-stock transaction valued, based on the closing market price of Pfizer’s common stock on the acquisition date, at $50.40 per share of Wyeth common stock, or a total of approximately $68 billion.
In response to the challenging operating environment, we have taken many steps to strengthen our Company and better position ourselves for the future. The most important of these steps was the acquisition of Wyeth, which has transformed us into a more diversified health care company, with product offerings in human and animal health, including vaccines, biologics, small molecules and nutrition across developed and emerging markets. We believe that our acquisition of Wyeth meaningfully advances, in a single transaction, each of the strategic priorities that we have identified and pursued over the last two years, including:
• Enhancing the in-line and patent-protected pipeline portfolio in key “invest to win” areas of
research where there exist significant unmet medical needs and significant opportunities for innovation and market leadership, such as oncology, pain, inflammation, Alzheimer’s disease, psychoses and diabetes as well as the critical technologies of vaccines and biologics;
• Becoming a top-tier player in biotherapeutics by 2015;
• Accelerating growth in emerging markets;
• Creating new opportunities for established products;
• Investing in complementary businesses; and
• Creating a lower, more flexible cost base for the combined company.
*Source: Form 10-K
. . . . .
Pfizer and plaintiffs settle lawsuits
http://flucrazy.blogspot.com/2011/02/pfizer-inc-nyse-pfe-and-plaintiffs.html
200 Largest Pharmaceutical Companies in the World
http://flucrazy.blogspot.com/2011/02/flucrazy-200-200-largest-pharmaceutical.html
Thursday, February 17, 2011
FluCrazy 200 - The 200 Largest Pharmaceutical Companies in the World
FluCrazy 200
Updated list for 2012 is here:
http://flucrazy.blogspot.com/2012/03/flu-crazy-200-largest-pharmaceutical.html
2011
The 200 Largest Pharmaceutical Companies in the World
(Alphabetical Order)
Abbott Laboratories
Acrux Limited
Alexion
ALK-Abello AS
Alkermes
Allergan
Amarin Corporation plc
Amylin Pharmaceuticals
Ardea Biosciences
ARIAD Pharmaceuticals
Astellas Pharma Inc.
AstraZeneca Pharma India
Aurobindo Pharma
Auxilium
Bavarian Nordic A/S
Baxter International
Bayer
Beijing Double-Crane
Beijing Tongrentang Co
Biocon Limited
Biogen Idec
BioMarin Pharmaceutical
Boiron S.A.
Bristol-Myers Squibb
Cadila Healthcare
Celgene Corporation
Celltrion Inc
Cephalon
Chengdu Hoist
Chongqing Huapont Pharmaceutical
Chongqing Taiji Industry
Chugai Pharmaceutical
Cipla
Clinical Data Inc
Cubist Pharmaceuticals
Da An Gene Co Ltd of Sun Yat-Sen University
Daiichi Sankyo
Dainippon Sumitomo
Dendreon
Divi's Laboratories
Dong-A Pharmaceutical Co
Dr. Reddy's Laboratories
EGIS NyRt
Eisai
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enzon Pharmaceuticals
Euromayor S.A. De Inversiones
Exelixis
F. Reichelt AG
Financiere de Tubize
Forest Laboratories
Gansu Duyiwei Biological
Genomma Lab Internacional SAB de CV
Geron Corp
GlaxoSmithKline
Glenmark Pharmaceuticals
Green Cross Corp
Guangzhou Baiyunshan
Guangzhou Pharmaceutical
Guizhou Bailing Group
Guizhou Yibai
H. Lundbeck
Hainan Honz Pharmaceutical Co
Halozyme Therapeutics
Harbin Pharm Group Sanjing
Harbin Pharmaceutical
Henan Topfond Pharmaceutical
Hikma Pharmaceuticals
Hisamitsu
Hospira
Huadong Medicine Co
Hubei Biocause Pharmaceutical Co
ImmunoGen Inc
Impax Laboratories
Intermune, Inc.
IPCA Laboratories
Jazz Pharmaceuticals
Jiangsu Hengrui Medicine
Jiangsu Kanion Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Jiangsu Sihuan Bioengineering
Jiangxi Jiangzhong Pharmaceutical
Jilin Aodong Medicine
Jinling Pharmaceutical
Jiuzhitang Co
Kaken Pharmaceutical
Kangmei
King Pharmaceuticals (acquired by Pfizer, Inc)
Kissei Pharmaceutical
Kobayashi Pharmaceutical Co
Krka, tovarna zdravil
Kunming Pharmaceutical
Kyorin
Kyowa Hakko Kirin
Lexicon Pharmaceuticals
LG Life Sciences
Livzon
Lupin
Max India
MaYinglong Pharmaceutical
Medicines Company
Medicis Pharmaceutical
Merck
Merck KGaA
Merro Pharmaceutical
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mylan
Myriad Genetics
Nektar Therapeutics
Nichi-iko Pharmaceutical
Nippon Shinyaku Co
North China Pharmaceutical
Northeast Pharmaceutical
Novo-Nordisk
Ono Pharmaceutical
ONYX Pharmaceuticals
Opko Health Inc
Orion Oyj
Par Pharmaceutical
Perrigo
Pfizer (India)
Pfizer Inc.
Pharmasset
Pharmstandard JSC
Piramal Healthcare
PKU International
Prestige Brands Holdings
Protek OAO
PT Kalbe Farma
Qingdao Huaren Pharmaceutical
Q-Med AB
Questcor Pharmaceuticals
Ranbaxy Laboratories
Recordati
Regeneron Pharmaceuticals
Richter Gedeon Nyrt
Rohto Pharmaceutical
Salix
Sanofi-Aventis
Santen Pharmaceutical
Savient Pharmaceuticals
Sawai Pharmaceutical
Seikagaku Corp
Shandong Luoxin Pharmacy
Shanghai Fosun
Shanghai Kaibao Pharmaceutical
Shanghai Modern Pharmaceutical
Shanghai RAAS Blood Products
Shanxi Yabao Pharmaceutical
Shenzhen Accord
Shenzhen Salubris Pharmaceuticals Co
Shionogi
Shire PLC
Sichuan Kelun
SIGA Technologies
Simcere Pharmaceutical
Square Pharmaceuticals
STADA Arzneimittel
Stallergenes
Sun Pharmaceutical
Swedish Orphan Biovitrum AB
Taisho Pharmaceutical
Takeda Pharmaceutical
Targacept
Tempo Scan Pacific
Theravance
Tianjin Chase Sun Pharmaceutical
Tianjin Zhong Xin
Tibet Cheezheng Tibetan Medicine
Tibet Urban Development & Investment
Torii Pharmaceutical
Torrent Pharmaceuticals
Towa Pharmaceutical
Tsumura & Co.
TTY Biopharm
Unisplendour Guhan Group
United Therapeutics
Valeant Pharmaceuticals
Vertex
Virbac SA
ViroPharma
Vivus Inc
Watson Pharmaceuticals
Wockhardt
Xiangxue Pharmaceutical
Xinjiang Tecon Animal Husbandry Bio-Technology
YuHan Corp
Zeria Pharmaceutical
Zhangzhou Pientzehuang
Zhejiang Hisoar Pharmaceutical
Zhejiang Hisun
Zhejiang Huahai
Zhejiang Jianfeng Group
Zhejiang Medicine Co., Ltd.
Zhejiang Xianju Pharmaceutical
Zhuzhou Qianjin Pharmaceutical
Updated list for 2012 is here:
http://flucrazy.blogspot.com/2012/03/flu-crazy-200-largest-pharmaceutical.html
2011
The 200 Largest Pharmaceutical Companies in the World
(Alphabetical Order)
Abbott Laboratories
Acrux Limited
Alexion
ALK-Abello AS
Alkermes
Allergan
Amarin Corporation plc
Amylin Pharmaceuticals
Ardea Biosciences
ARIAD Pharmaceuticals
Astellas Pharma Inc.
AstraZeneca Pharma India
Aurobindo Pharma
Auxilium
Bavarian Nordic A/S
Baxter International
Bayer
Beijing Double-Crane
Beijing Tongrentang Co
Biocon Limited
Biogen Idec
BioMarin Pharmaceutical
Boiron S.A.
Bristol-Myers Squibb
Cadila Healthcare
Celgene Corporation
Celltrion Inc
Cephalon
Chengdu Hoist
Chongqing Huapont Pharmaceutical
Chongqing Taiji Industry
Chugai Pharmaceutical
Cipla
Clinical Data Inc
Cubist Pharmaceuticals
Da An Gene Co Ltd of Sun Yat-Sen University
Daiichi Sankyo
Dainippon Sumitomo
Dendreon
Divi's Laboratories
Dong-A Pharmaceutical Co
Dr. Reddy's Laboratories
EGIS NyRt
Eisai
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enzon Pharmaceuticals
Euromayor S.A. De Inversiones
Exelixis
F. Reichelt AG
Financiere de Tubize
Forest Laboratories
Gansu Duyiwei Biological
Genomma Lab Internacional SAB de CV
Geron Corp
GlaxoSmithKline
Glenmark Pharmaceuticals
Green Cross Corp
Guangzhou Baiyunshan
Guangzhou Pharmaceutical
Guizhou Bailing Group
Guizhou Yibai
H. Lundbeck
Hainan Honz Pharmaceutical Co
Halozyme Therapeutics
Harbin Pharm Group Sanjing
Harbin Pharmaceutical
Henan Topfond Pharmaceutical
Hikma Pharmaceuticals
Hisamitsu
Hospira
Huadong Medicine Co
Hubei Biocause Pharmaceutical Co
ImmunoGen Inc
Impax Laboratories
Intermune, Inc.
IPCA Laboratories
Jazz Pharmaceuticals
Jiangsu Hengrui Medicine
Jiangsu Kanion Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Jiangsu Sihuan Bioengineering
Jiangxi Jiangzhong Pharmaceutical
Jilin Aodong Medicine
Jinling Pharmaceutical
Jiuzhitang Co
Kaken Pharmaceutical
Kangmei
King Pharmaceuticals (acquired by Pfizer, Inc)
Kissei Pharmaceutical
Kobayashi Pharmaceutical Co
Krka, tovarna zdravil
Kunming Pharmaceutical
Kyorin
Kyowa Hakko Kirin
Lexicon Pharmaceuticals
LG Life Sciences
Livzon
Lupin
Max India
MaYinglong Pharmaceutical
Medicines Company
Medicis Pharmaceutical
Merck
Merck KGaA
Merro Pharmaceutical
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mylan
Myriad Genetics
Nektar Therapeutics
Nichi-iko Pharmaceutical
Nippon Shinyaku Co
North China Pharmaceutical
Northeast Pharmaceutical
Novo-Nordisk
Ono Pharmaceutical
ONYX Pharmaceuticals
Opko Health Inc
Orion Oyj
Par Pharmaceutical
Perrigo
Pfizer (India)
Pfizer Inc.
Pharmasset
Pharmstandard JSC
Piramal Healthcare
PKU International
Prestige Brands Holdings
Protek OAO
PT Kalbe Farma
Qingdao Huaren Pharmaceutical
Q-Med AB
Questcor Pharmaceuticals
Ranbaxy Laboratories
Recordati
Regeneron Pharmaceuticals
Richter Gedeon Nyrt
Rohto Pharmaceutical
Salix
Sanofi-Aventis
Santen Pharmaceutical
Savient Pharmaceuticals
Sawai Pharmaceutical
Seikagaku Corp
Shandong Luoxin Pharmacy
Shanghai Fosun
Shanghai Kaibao Pharmaceutical
Shanghai Modern Pharmaceutical
Shanghai RAAS Blood Products
Shanxi Yabao Pharmaceutical
Shenzhen Accord
Shenzhen Salubris Pharmaceuticals Co
Shionogi
Shire PLC
Sichuan Kelun
SIGA Technologies
Simcere Pharmaceutical
Square Pharmaceuticals
STADA Arzneimittel
Stallergenes
Sun Pharmaceutical
Swedish Orphan Biovitrum AB
Taisho Pharmaceutical
Takeda Pharmaceutical
Targacept
Tempo Scan Pacific
Theravance
Tianjin Chase Sun Pharmaceutical
Tianjin Zhong Xin
Tibet Cheezheng Tibetan Medicine
Tibet Urban Development & Investment
Torii Pharmaceutical
Torrent Pharmaceuticals
Towa Pharmaceutical
Tsumura & Co.
TTY Biopharm
Unisplendour Guhan Group
United Therapeutics
Valeant Pharmaceuticals
Vertex
Virbac SA
ViroPharma
Vivus Inc
Watson Pharmaceuticals
Wockhardt
Xiangxue Pharmaceutical
Xinjiang Tecon Animal Husbandry Bio-Technology
YuHan Corp
Zeria Pharmaceutical
Zhangzhou Pientzehuang
Zhejiang Hisoar Pharmaceutical
Zhejiang Hisun
Zhejiang Huahai
Zhejiang Jianfeng Group
Zhejiang Medicine Co., Ltd.
Zhejiang Xianju Pharmaceutical
Zhuzhou Qianjin Pharmaceutical
Wednesday, February 16, 2011
Study shows no drop in rate of childhood pneumonia after vaccine
A study on the rates of childhood pneumonia shows no difference in the number of cases after the vaccine became available. Pfizer's (PFE) vaccine "Prevnar" cited.
According to Reuters, in "the first study to provide national estimates of childhood pneumonia, they found rates of the lung infection had stayed more or less constant between 1994 and 2007.
At the beginning of that period, 19 in 1,000 children got a pneumonia diagnosis at the doctor's office or at an emergency department, compared to 22 in 1,000 at the end.
But that doesn't mean the vaccine -- Pfizer's Prevnar, or PCV7 -- has been useless.
For instance, earlier work found the number of kids who had to be treated for pneumonia at the hospital dropped by more than half after the vaccine became available.
"It's possible that the vaccination has had a major impact on the more serious complications of pneumonia," said Dr. Samir S. Shah of the University of Pennsylvania School of Medicine in Philadelphia, who led the work.
Prevnar protects against a type of bacteria called Streptococcus pneumoniae, or just pneumococcus, which causes several kinds of infections -- including pneumonia, meningitis and middle ear infections.
"If you look at how effective the vaccine was in reducing meningitis and blood infections, it has done a phenomenal job," said Shah, whose study was supported by the National Institutes of Health.
While Pfizer said Prevnar is not licensed to prevent pneumonia in the U.S., it stressed the new study's design might be shrouding possible effects of the vaccine on the disease."
#flu #pharma "pfizer"
According to Reuters, in "the first study to provide national estimates of childhood pneumonia, they found rates of the lung infection had stayed more or less constant between 1994 and 2007.
At the beginning of that period, 19 in 1,000 children got a pneumonia diagnosis at the doctor's office or at an emergency department, compared to 22 in 1,000 at the end.
But that doesn't mean the vaccine -- Pfizer's Prevnar, or PCV7 -- has been useless.
For instance, earlier work found the number of kids who had to be treated for pneumonia at the hospital dropped by more than half after the vaccine became available.
"It's possible that the vaccination has had a major impact on the more serious complications of pneumonia," said Dr. Samir S. Shah of the University of Pennsylvania School of Medicine in Philadelphia, who led the work.
Prevnar protects against a type of bacteria called Streptococcus pneumoniae, or just pneumococcus, which causes several kinds of infections -- including pneumonia, meningitis and middle ear infections.
"If you look at how effective the vaccine was in reducing meningitis and blood infections, it has done a phenomenal job," said Shah, whose study was supported by the National Institutes of Health.
While Pfizer said Prevnar is not licensed to prevent pneumonia in the U.S., it stressed the new study's design might be shrouding possible effects of the vaccine on the disease."
#flu #pharma "pfizer"
Thursday, February 10, 2011
Report says Pfizer (NYSE: PFE) will pay approx $ 330 million to settle claims related to the Prempro menopause drug.
A report by Bloomberg says Pfizer (NYSE: PFE) will pay approximately $ 330 million to settle claims related to the Prempro menopause drug.
http://www.bloomberg.com/news/2010-08-27/pfizer-settles-arkansas-prempro-case-before-retrial-over-punitive-damages.html
"The drugmaker faced more than 10,000 claims that its menopause drugs caused breast cancer prior the settlements, which were reached during the past five months, the people said. That number included more than 8,000 cases consolidated in federal court in Arkansas and other cases in state courts in Pennsylvania, Nevada and Minnesota."
Pfizer is facing numerous suits claiming that its hormone replacement therapy caused breast cancer.
http://www.bloomberg.com/news/2010-08-27/pfizer-settles-arkansas-prempro-case-before-retrial-over-punitive-damages.html
"The drugmaker faced more than 10,000 claims that its menopause drugs caused breast cancer prior the settlements, which were reached during the past five months, the people said. That number included more than 8,000 cases consolidated in federal court in Arkansas and other cases in state courts in Pennsylvania, Nevada and Minnesota."
Pfizer is facing numerous suits claiming that its hormone replacement therapy caused breast cancer.
Subscribe to:
Posts (Atom)